title: Changes following supplementation with lutein and zeaxanthin in retinal function in eyes with early age-related macular degeneration: a randomised, double-blind, placebo-controlled trial.
abstract: OBJECTIVE
  To investigate functional and macular pigment (MP) changes in patients with early age-related macular degeneration (AMD) after multiple supplementation with lutein and zeaxanthin.
  
  
  METHODS
  112 patients with early AMD were randomly (1:1:1:1) assigned to receive 10 mg lutein, 20 mg lutein, lutein (10 mg)+zeaxanthin (10 mg), or placebo daily for 2 years. MP optical density (MPOD) was recorded at baseline, 48 weeks and 2 years. Retinal sensitivities were measured by multifocal electroretinogram for peak-to-trough amplitude (N1P1) at baseline and at 48 weeks, and in terms of microperimeter-determined mean retinal sensitivity (MRS) at 48 weeks and 2 years.
  
  
  RESULTS
  Supplementation with lutein and zeaxanthin augmented MPOD significantly in active treatment groups (all p<0.05). N1P1 response densities showed significant increases in ring 1 and ring 2 after 48 weeks of supplementation, while no significant changes were seen in rings 3-6. Significant increases in MRS were detected after supplementation with either 10 or 20 mg lutein, whereas no such increases were seen in the placebo arm.
  
  
  CONCLUSIONS
  Supplementation with lutein and/or zeaxanthin increases MPOD, and supplemental lutein enhances retinal sensitivity, in patients with early AMD.
  
  
  BACKGROUND
  Clinicaltrials.gov NCT10528605.
authors.affiliation: School of Public Health, Peking University, Beijing, China.
authors.forename: Yang-Mu
authors.initials: YM
authors.lastname: Huang
authors.affiliation: Peking University Eye Center, Peking University Third Hospital, Beijing, China.
authors.forename: Hong-Liang
authors.initials: HL
authors.lastname: Dou
authors.affiliation: School of Public Health, Peking University, Beijing, China.
authors.forename: Fei-Fei
authors.initials: FF
authors.lastname: Huang
authors.affiliation: School of Public Health, Peking University, Beijing, China.
authors.forename: Xian-Rong
authors.initials: XR
authors.lastname: Xu
authors.affiliation: School of Public Health, Peking University, Beijing, China.
authors.forename: Zhi-Yong
authors.initials: ZY
authors.lastname: Zou
authors.affiliation: Peking University Eye Center, Peking University Third Hospital, Beijing, China.
authors.forename: Xin-Rong
authors.initials: XR
authors.lastname: Lu
authors.affiliation: School of Public Health, Peking University, Beijing, China.
authors.forename: Xiao-Ming
authors.initials: XM
authors.lastname: Lin
mesh_terms: D000368:Aged; D019587:Dietary Supplements; D004311:Double-Blind Method; D004338:Drug Combinations; D004596:Electroretinography; D005260:Female; D006801:Humans; D014975:Lutein / Q000008:administration & dosage*; D008268:Macular Degeneration / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D065348:Macular Pigment / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D012160:Retina / Q000502:physiology*; D011795:Surveys and Questionnaires; D058609:Visual Field Tests; D014794:Visual Fields / Q000502:physiology; D065146:Zeaxanthins / Q000008:administration & dosage*
chemical_list: D004338:Drug Combinations; D065348:Macular Pigment; D065146:Zeaxanthins; D014975:Lutein
keywords: Clinical Trial; Degeneration; Macula